BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst (Nasdaq:BCRX) announced inducement restricted stock unit grants to six newly hired employees covering an aggregate of 65,850 RSUs, granted as of March 2, 2026 under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst (Nasdaq:BCRX) announced inducement restricted stock unit grants to six newly hired employees covering an aggregate of 65,850 RSUs, granted as of March 2, 2026 under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date and are subject to the company’s Inducement Equity Incentive Plan and individual RSU agreements.
Details
News Market Reaction – BCRX
On Mar 4, the day this news came out, BCRX closed 1.38% below the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- RSU shares granted
- 65,850 shares
- Aggregate RSUs to six new employees as of March 2, 2026
- Employees granted RSUs
- 6 employees
- Newly hired employees receiving inducement RSUs
- Vesting schedule
- 4 annual installments
- RSUs vest over four years, starting one year after grant
- Grant date
- March 2, 2026
- Date RSUs were granted under Nasdaq Listing Rule 5635(c)(4)
Historical Context
-
Record 2025 revenue, operating profit, and maintained 2026 revenue guidance.
-
Announcement of participation at major health care investor conference.
-
Multiple HAE abstracts including ORLADEYO and navenibart interim results.
-
Scheduling of Q4 2025 results call and webcast logistics.
-
Stock options and RSUs granted to 24 new hires under inducement plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units (rsus) financial
nasdaq listing rule 5635(c)(4) regulatory
inducement equity incentive plan financial
restricted stock unit agreement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,850 shares of BioCryst common stock. The RSUs were granted as of March 2, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.